Efficacy of Perampanel as a Monotherapy for Seizure Control During Awake Craniotomy in Glioma Patients

Category	Detail
Condition	Intraoperative seizures during awake craniotomy for glioma resection
Key Mechanisms	Perampanel as a single-agent prophylactic treatment to prevent intraoperative seizures
Target Population	Patients with supratentorial glioma undergoing awake craniotomy
Care Setting	Neurosurgery department in a hospital setting

Awake craniotomy allows for maximal safe resection of gliomas while preserving neurological function
Intraoperative seizures can complicate procedures and may require conversion to general anesthesia
Perampanel monotherapy initiated preoperatively may reduce the incidence of intraoperative seizures
The study included 29 patients with specific inclusion and exclusion criteria
Postoperative seizure management was tailored based on preoperative regimens

Monitor for intraoperative seizures using electrocorticography during awake craniotomy

Administer Perampanel as a prophylactic agent starting at least 3 days before surgery

Evaluate seizure outcomes postoperatively within one week and up to three months

Intraoperative seizures can lead to increased intracranial pressure and neurological deterioration

29 patients with supratentorial glioma undergoing awake craniotomy

Perampanel was given at an initial dose of 2 mg, with adjustments based on clinical condition

Utilize awake craniotomy for gliomas in eloquent brain regions to minimize neurological deficits
Implement continuous electrocorticography to monitor for seizures during surgery
Use cold saline irrigation to manage intraoperative seizures effectively

Clinical Scorecard: Efficacy of Perampanel as a Monotherapy for Seizure Control During Awake Craniotomy in Glioma Patients